阿托伐他汀早期干预对急性冠状动脉综合征患者C-反应蛋白和血脂的影响  

Therapeutic effects of atorvastatin on serum lipids and C - reactive protein in patients with acute coronary syndrome at the early stage

作　　者：刘军委[1] 

机构地区：[1]河南省商丘市第一人民医院,476100

出　　处：《中国实用医刊》2009年第12期23-24,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨阿托伐他汀对忽性冠状动脉综合征（ACS）患者血清C-反应蛋白（CRP）水平和血脂的影响。方法70例ACS患者随机分为阿托伐他汀组（35例）和对照组（35例），分别测定治疗前后CRP、甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL—C）、高密度脂蛋白胆固醇（I-IDL—C）。结果治疗4周后，阿托伐他汀组与对照组相比，患者血清CRP和TC、TG及LDL—C浓度显著降低（P均〈0．01），而对照组治疗前后差异无统计学意义（P〉0．05）。结论ACS患者血清CPR水平增高，早期应用阿托伐他汀能安全、有效地降低血脂和CRP，升高HDL—C。Objective To explore the effects of atorvastatin on serum C - reactive protein in patients with acute coronary syndrome （ACS）. Methods Seventy cases of ACS patients were randomly divided into atorvastatin group （ n = 35） and control group （ n = 35 ）. The serum CRP and lipoprotein were measured in 70 patients with ACS before and after treatment. Results After 4 weeks, the atorvastatingroup and control group, patients with CRP and serum total cholesterol （TC）, triglycerides （TG） and low - density lipoprotein cholesterol （ LDL - C） concentration decreased significantly （ P 〈 0.01 ）, while the control group before and after treatment the difference was not significant （ P 〉 0.05）. Conclusions The serum levels of CRP are increased in patients with ACS. Atorvastatin is an effective and safe lipid - lowering drug,it can decrease CRP and increase HDL- C in plasma level.

关 键 词：阿托伐他汀 C-反应蛋白 冠状动脉疾病 

分 类 号：R541.4[医药卫生—心血管疾病]